Latest Anastrozole Stories
Experimental drug may help reprogram tumor cells to respond to hormone therapy BALTIMORE, June 2, 2011 /PRNewswire-USNewswire/ -- A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.
In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.
Recent research indicates medications such as Tamoxifen or Raloxifene considerably reduce the risk of developing breast cancer in post-menopausal women.
Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs.
WALTHAM, Mass., March 1, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
Postmenopausal women fighting a specific form of breast cancer may get some help through innovative use of two enzyme-inhibiting drugs.
Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease.
NEW YORK, Oct.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.